TITLE:
Study Evaluating TMI-005 in Active Rheumatoid Arthritis

CONDITION:
Rheumatoid Arthritis

INTERVENTION:
TMI-005

SUMMARY:

      The primary objective of this clinical research study is to compare the efficacy and the
      safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active
      Rheumatoid Arthritis (RA) who have been receiving stable doses of Methotrexate (MTX).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Meet American College of Rheumatology (ACR) criteria for RA

          -  Have active RA

          -  Disease duration of at least 6 months

          -  Disease onset at > 16 years of age.

        Exclusion Criteria:

          -  Any prior use of anti-TNF alpha biologics, rituximab, receipt of anti-CD4 or
             diphtheria interleukin-2 fusion protein or other immunosuppressive biologics (except
             for anakinra)

          -  Largely or wholly incapacitated with the subject bedridden or confined to a
             wheelchair, permitting limited or no self-care

          -  Pregnant or breastfeeding women or women planning to become pregnant during the study
             or within 12 weeks after the last dose of test article
      
